Melissa Erce

Senior Associate
Registered Patent Attorney

Melissa is a Registered Australian and New Zealand Patent Attorney specialising in Biotechnology.  Her practice includes preparing and prosecuting patent applications, coordinating prosecution of global patent portfolios and providing patentability opinions.

Melissa has a PhD in Biochemistry and Molecular Genetics from UNSW and was a post-doctoral Research Associate prior to becoming a Patent Attorney.  During her research career, Melissa studied the role of post-translational modifications in protein interactions and her work involved building a system to determine how post-translational modifications affected a protein’s capacity to interact with its partners.  Melissa’s research has been published in well-regarded journals including Molecular & Cellular Proteomics, the Journal of Molecular Biology, Proteomics and the Journal of Proteome Research.

Melissa’s technical background leaves her well-placed to assist clients in a range of sectors in the life science space and she has extensive experience in prosecuting patent applications in a range of technology areas including gene silencing, gene editing, cloning and expression, antibodies and immunology, therapeutics, proteomics and diagnostics.  Melissa has experience in acting for a wide variety of clients spanning from early start ups to research institutes, universities and multinationals.

Melissa holds a Master of Intellectual Property and is a member of the Institute of Patent and Trade Mark Attorneys of Australia (IPTA) and the Intellectual Property Society of Australia and New Zealand (IPSANZ).


David Müller-Wiesner

Contact Melissa

phone +61 2 7208 9500



Insights from the Team

IP STARS Ranking and New Arrival

by | Jul 9, 2024 | Firm News | 0 Comments

Biotechnology Expansion We are pleased to introduce the most recent addition to our team, Melissa Erce.  Mel joins us after many years working in large IP firms,...

IP Stars Ranking for Trade Marks

by | May 21, 2024 | Firm News | 0 Comments

We are excited to announce that GLMR has been ranked by IP STARS as a notable firm for Trade Mark Prosecution.  Our amazing Trade Marks Team has been working tirelessly...

2023 Award Season Wrap-up

by | Jan 12, 2024 | Firm News | 0 Comments

It has been a busy year, and the excellence of our IP team in Australia and New Zealand has been recognised by a gamut of organisations. We're proud of these wins and...

Design Law Updates and the Effective Use of Design Patents

by | Jul 3, 2023 | Designs | 0 Comments

GLMR and Kilpatrick Townsend jointly presented a webinar entitled Design Law Updates and the Effective Use of Design Patents. The webinar was presented by Michelle Lee,...

GLMR congratulates David Bayliss and Edward Quinn

by | Apr 4, 2023 | Firm News | 0 Comments

While significant milestones are achieved in a fast-growing firm with a rapid frequency, it is important to recognise achievements in personal and team development....

NZ Computer Implemented Inventions

New Zealand Patent Office finds computer implemented invention patentable

by | Jan 18, 2023 | Patents | 0 Comments

In a recent hearing decision, IsoLynx, LLC [2022] NZIPOPAT 16, the New Zealand Patent Office (IPONZ) has confirmed that certain computer implemented inventions are...

Australian patentable subject matter test after Aristocrat

by | Jan 17, 2023 | Patents | 0 Comments

In a recent hearing decision, the Australian Patent Office has provided insight into the application of the patentable subject matter test, post the High Court’s split...

Aristocrat rolls snake eyes, but there is a silver lining

by | Aug 22, 2022 | Patents | 0 Comments

In an unusual result, the High Court of Australia has returned an equally divided decision in Aristocrat Technologies Australia Pty Ltd v Commissioner of Patents [2022]...

GLMR Supports Startup Ecosystem

by | Aug 22, 2022 | Firm News | 0 Comments

We are proud to announce our continued sponsorship of the UTS Startups Awards in 2022, with a cash prize of $1000 together with an IP audit valued at $1000. The...